Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders
- PMID: 26997580
- DOI: 10.1111/obr.12385
Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders
Abstract
Phosphodiesterase-4 (PDE4) hydrolyses cyclic adenosine monophosphate (cAMP), a crucial secondary messenger for cellular adaptation to diverse external stimuli. The activity of PDE4 is tightly controlled by post-translational regulation, structure-based auto-regulation and locus specific 'compartmentalization' of PDE4 with its interactive proteins (signalsomes). Through these mechanisms, PDE4 regulates cAMP levels and shapes the cAMP signalling, directing signals from the diverse external stimuli to distinct microenvironments exquisitely. Derangement of the PDE4-cAMP signalling represents a pathophysiologically relevant pathway in metabolic disorders as demonstrated through a critical role in the processes including inflammation, disordered glucose and lipid metabolism, hepatic steatosis, abnormal lipolysis, suppressed thermogenic function and deranged neuroendocrine functions. A limited number of PDE4 inhibitors are currently undergoing clinical evaluation for treating disorders such as type 2 diabetes and non-alcoholic steatohepatitis. The discovery of novel PDE4 allosteric inhibitors and signalsome-based strategies _targeting individual PDE4 variants may allow PDE4 isoform selective inhibition, which may offer safer strategies for chronic treatment of metabolic disorders.
Keywords: cyclic adenosine monophosphate; metabolic disorders; phosphodiesterase-4.
© 2016 World Obesity.
Similar articles
-
Dysregulation of hepatic cAMP levels via altered Pde4b expression plays a critical role in alcohol-induced steatosis.J Pathol. 2016 Sep;240(1):96-107. doi: 10.1002/path.4760. J Pathol. 2016. PMID: 27287961 Free PMC article.
-
Phosphodiesterase-4 enzyme as a therapeutic _target in neurological disorders.Pharmacol Res. 2020 Oct;160:105078. doi: 10.1016/j.phrs.2020.105078. Epub 2020 Jul 14. Pharmacol Res. 2020. PMID: 32673703 Review.
-
Advances in the Development of Phosphodiesterase-4 Inhibitors.J Med Chem. 2020 Oct 8;63(19):10594-10617. doi: 10.1021/acs.jmedchem.9b02170. Epub 2020 Jun 10. J Med Chem. 2020. PMID: 32255344 Review.
-
_targeting phosphodiesterase 4 as a therapeutic strategy for cognitive improvement.Bioorg Chem. 2023 Jan;130:106278. doi: 10.1016/j.bioorg.2022.106278. Epub 2022 Nov 17. Bioorg Chem. 2023. PMID: 36413930 Review.
-
Phosphodiesterase inhibitors in the treatment of inflammatory diseases.Handb Exp Pharmacol. 2011;(204):391-414. doi: 10.1007/978-3-642-17969-3_17. Handb Exp Pharmacol. 2011. PMID: 21695650 Review.
Cited by
-
Efficacy and Metabolic Effect on Serum Lipids of Apremilast in Psoriatic Arthritis: A Case Report.J Clin Med. 2019 Mar 22;8(3):398. doi: 10.3390/jcm8030398. J Clin Med. 2019. PMID: 30909370 Free PMC article.
-
Inhibition of type 4 cAMP-phosphodiesterases (PDE4s) in mice induces hypothermia via effects on behavioral and central autonomous thermoregulation.Biochem Pharmacol. 2020 Oct;180:114158. doi: 10.1016/j.bcp.2020.114158. Epub 2020 Jul 20. Biochem Pharmacol. 2020. PMID: 32702371 Free PMC article.
-
Role of Phosphodiesterase in the Biology and Pathology of Diabetes.Int J Mol Sci. 2020 Nov 3;21(21):8244. doi: 10.3390/ijms21218244. Int J Mol Sci. 2020. PMID: 33153226 Free PMC article. Review.
-
qPCR Analysis Reveals Association of Differential Expression of SRR, NFKB1, and PDE4B Genes With Type 2 Diabetes Mellitus.Front Endocrinol (Lausanne). 2022 Jan 3;12:774696. doi: 10.3389/fendo.2021.774696. eCollection 2021. Front Endocrinol (Lausanne). 2022. PMID: 35046895 Free PMC article.
-
The Effect of Roflumilast on Lipopolysaccharide-induced Acute Lung Injury During Neutropenia Recovery in Mice.In Vivo. 2024 May-Jun;38(3):1127-1132. doi: 10.21873/invivo.13547. In Vivo. 2024. PMID: 38688656 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
